Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach

Han Ting Liu, Chiun Hsu, Chi Long Chen, I. Ping Chiang, Li Tzong Chen, Yao Chang Chen, Ann Lii Cheng

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The optimal treatment of localized large-cell lymphoma of the stomach remains controversial. In particular, the role of surgical resection of the primary tumor needs to be clearly defined. We have reviewed all patients with a diagnosis of gastric lymphoma and treated in our institutions between 1988 and 1998. Patients fulfilling the following criteria were included in this study: (1) histologically proven large-cell lymphoma of the stomach; (2) adequate pathological materials and complete clinical information for analysis; (3) clinical stage I/II disease according to the Musshoff modification of Ann Arbor system; and (4) received primary chemotherapy alone with anthracycline- or anthracenedione-containing regimens (group A) or curative surgery followed by adjuvant chemotherapy (group B). There were 38 and 21 patients in group A and group B, respectively. All pertinent clinicopathologic features were similar between the two groups of patients, except that patients of group A had significantly more stage II-2 disease (P = 0.004). Of group A, among 36 patients who could be evaluated for response to chemotherapy, there were 29 complete and 1 partial responses, with an overall response rate of 83.3% (95% Cl, 71.1-95.5%). The projected 5-year relapse-free survival (RFS) and overall survival (OS) were 86.0% (95% Cl, 73.3-98.7%) and 72.6% (95% Cl, 57.0-88.2%), respectively. On the other hand, the projected 5-year RFS and OS of group B were 77.9% (95% Cl, 58.0-97.8%) and 77.8% (95% Cl, 57.9-97.7%), respectively, not significantly different from that of group A. Our data suggest that systemic chemotherapy alone may be a reasonable alternative treatment for stage I/II large-cell lymphoma of the stomach. Resection of the primary tumor before systemic chemotherapy does not appear to improve the cure rate of this group of patients. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)175-179
Number of pages5
JournalAmerican Journal of Hematology
Volume64
Issue number3
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Lymphoma
Stomach
Drug Therapy
Survival
Recurrence
Anthraquinones
Anthracyclines
Adjuvant Chemotherapy
Neoplasms
Therapeutics

Keywords

  • Chemotherapy
  • Gastric lymphoma
  • Surgery

ASJC Scopus subject areas

  • Hematology

Cite this

Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. / Liu, Han Ting; Hsu, Chiun; Chen, Chi Long; Chiang, I. Ping; Chen, Li Tzong; Chen, Yao Chang; Cheng, Ann Lii.

In: American Journal of Hematology, Vol. 64, No. 3, 2000, p. 175-179.

Research output: Contribution to journalArticle

Liu, Han Ting ; Hsu, Chiun ; Chen, Chi Long ; Chiang, I. Ping ; Chen, Li Tzong ; Chen, Yao Chang ; Cheng, Ann Lii. / Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. In: American Journal of Hematology. 2000 ; Vol. 64, No. 3. pp. 175-179.
@article{ad27b9f281bf4e05b7339754d113440e,
title = "Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach",
abstract = "The optimal treatment of localized large-cell lymphoma of the stomach remains controversial. In particular, the role of surgical resection of the primary tumor needs to be clearly defined. We have reviewed all patients with a diagnosis of gastric lymphoma and treated in our institutions between 1988 and 1998. Patients fulfilling the following criteria were included in this study: (1) histologically proven large-cell lymphoma of the stomach; (2) adequate pathological materials and complete clinical information for analysis; (3) clinical stage I/II disease according to the Musshoff modification of Ann Arbor system; and (4) received primary chemotherapy alone with anthracycline- or anthracenedione-containing regimens (group A) or curative surgery followed by adjuvant chemotherapy (group B). There were 38 and 21 patients in group A and group B, respectively. All pertinent clinicopathologic features were similar between the two groups of patients, except that patients of group A had significantly more stage II-2 disease (P = 0.004). Of group A, among 36 patients who could be evaluated for response to chemotherapy, there were 29 complete and 1 partial responses, with an overall response rate of 83.3{\%} (95{\%} Cl, 71.1-95.5{\%}). The projected 5-year relapse-free survival (RFS) and overall survival (OS) were 86.0{\%} (95{\%} Cl, 73.3-98.7{\%}) and 72.6{\%} (95{\%} Cl, 57.0-88.2{\%}), respectively. On the other hand, the projected 5-year RFS and OS of group B were 77.9{\%} (95{\%} Cl, 58.0-97.8{\%}) and 77.8{\%} (95{\%} Cl, 57.9-97.7{\%}), respectively, not significantly different from that of group A. Our data suggest that systemic chemotherapy alone may be a reasonable alternative treatment for stage I/II large-cell lymphoma of the stomach. Resection of the primary tumor before systemic chemotherapy does not appear to improve the cure rate of this group of patients. (C) 2000 Wiley-Liss, Inc.",
keywords = "Chemotherapy, Gastric lymphoma, Surgery",
author = "Liu, {Han Ting} and Chiun Hsu and Chen, {Chi Long} and Chiang, {I. Ping} and Chen, {Li Tzong} and Chen, {Yao Chang} and Cheng, {Ann Lii}",
year = "2000",
doi = "10.1002/1096-8652(200007)64:3<175::AID-AJH6>3.0.CO;2-7",
language = "English",
volume = "64",
pages = "175--179",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach

AU - Liu, Han Ting

AU - Hsu, Chiun

AU - Chen, Chi Long

AU - Chiang, I. Ping

AU - Chen, Li Tzong

AU - Chen, Yao Chang

AU - Cheng, Ann Lii

PY - 2000

Y1 - 2000

N2 - The optimal treatment of localized large-cell lymphoma of the stomach remains controversial. In particular, the role of surgical resection of the primary tumor needs to be clearly defined. We have reviewed all patients with a diagnosis of gastric lymphoma and treated in our institutions between 1988 and 1998. Patients fulfilling the following criteria were included in this study: (1) histologically proven large-cell lymphoma of the stomach; (2) adequate pathological materials and complete clinical information for analysis; (3) clinical stage I/II disease according to the Musshoff modification of Ann Arbor system; and (4) received primary chemotherapy alone with anthracycline- or anthracenedione-containing regimens (group A) or curative surgery followed by adjuvant chemotherapy (group B). There were 38 and 21 patients in group A and group B, respectively. All pertinent clinicopathologic features were similar between the two groups of patients, except that patients of group A had significantly more stage II-2 disease (P = 0.004). Of group A, among 36 patients who could be evaluated for response to chemotherapy, there were 29 complete and 1 partial responses, with an overall response rate of 83.3% (95% Cl, 71.1-95.5%). The projected 5-year relapse-free survival (RFS) and overall survival (OS) were 86.0% (95% Cl, 73.3-98.7%) and 72.6% (95% Cl, 57.0-88.2%), respectively. On the other hand, the projected 5-year RFS and OS of group B were 77.9% (95% Cl, 58.0-97.8%) and 77.8% (95% Cl, 57.9-97.7%), respectively, not significantly different from that of group A. Our data suggest that systemic chemotherapy alone may be a reasonable alternative treatment for stage I/II large-cell lymphoma of the stomach. Resection of the primary tumor before systemic chemotherapy does not appear to improve the cure rate of this group of patients. (C) 2000 Wiley-Liss, Inc.

AB - The optimal treatment of localized large-cell lymphoma of the stomach remains controversial. In particular, the role of surgical resection of the primary tumor needs to be clearly defined. We have reviewed all patients with a diagnosis of gastric lymphoma and treated in our institutions between 1988 and 1998. Patients fulfilling the following criteria were included in this study: (1) histologically proven large-cell lymphoma of the stomach; (2) adequate pathological materials and complete clinical information for analysis; (3) clinical stage I/II disease according to the Musshoff modification of Ann Arbor system; and (4) received primary chemotherapy alone with anthracycline- or anthracenedione-containing regimens (group A) or curative surgery followed by adjuvant chemotherapy (group B). There were 38 and 21 patients in group A and group B, respectively. All pertinent clinicopathologic features were similar between the two groups of patients, except that patients of group A had significantly more stage II-2 disease (P = 0.004). Of group A, among 36 patients who could be evaluated for response to chemotherapy, there were 29 complete and 1 partial responses, with an overall response rate of 83.3% (95% Cl, 71.1-95.5%). The projected 5-year relapse-free survival (RFS) and overall survival (OS) were 86.0% (95% Cl, 73.3-98.7%) and 72.6% (95% Cl, 57.0-88.2%), respectively. On the other hand, the projected 5-year RFS and OS of group B were 77.9% (95% Cl, 58.0-97.8%) and 77.8% (95% Cl, 57.9-97.7%), respectively, not significantly different from that of group A. Our data suggest that systemic chemotherapy alone may be a reasonable alternative treatment for stage I/II large-cell lymphoma of the stomach. Resection of the primary tumor before systemic chemotherapy does not appear to improve the cure rate of this group of patients. (C) 2000 Wiley-Liss, Inc.

KW - Chemotherapy

KW - Gastric lymphoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0034125782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034125782&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200007)64:3<175::AID-AJH6>3.0.CO;2-7

DO - 10.1002/1096-8652(200007)64:3<175::AID-AJH6>3.0.CO;2-7

M3 - Article

VL - 64

SP - 175

EP - 179

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -